{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:54:04Z","timestamp":1791060844286,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001633 \/ MOH-STaR24jan-0001"],"award-info":[{"award-number":["MOH-001633 \/ MOH-STaR24jan-0001"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omton.2026.201335","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:49:00Z","timestamp":1788479340000},"page":"201335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering \u201coff-the-shelf\u201d TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality"],"prefix":"10.1016","volume":"34","author":[{"given":"Shan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou Kit","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-1043","authenticated-orcid":false,"given":"Andrea","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-1079","authenticated-orcid":false,"given":"Thinesh","family":"Lee Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0079-8203","authenticated-orcid":false,"given":"Anthony Tanoto","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201335_bib1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41423-023-01080-3","article-title":"Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy","volume":"20","author":"Chen","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201335_bib2","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201335_bib3","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omton.2026.201335_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omton.2026.201335_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.43","article-title":"A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus","volume":"2","author":"Koh","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201335_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omton.2026.201335_bib7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.omton.2026.201335_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep4.1857","article-title":"Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC","volume":"6","author":"Tan","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.omton.2026.201335_bib9","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1158\/1078-0432.CCR-25-1245","article-title":"HBV-Specific TCR\u2013T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation","volume":"31","author":"Zhao","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201335_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201335_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201335_bib12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive Lymphoma after CD19 CAR T-Cell Therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201335_bib13","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201335_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.ymthe.2025.02.012","article-title":"Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity","volume":"33","author":"Cheng","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201335_bib15","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/ajt.12475","article-title":"Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive Immunotherapy","volume":"13","author":"Ricciardelli","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omton.2026.201335_bib16","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","article-title":"Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease","volume":"114","author":"Brewin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201335_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.omton.2026.201335_bib18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell\u2013like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201335_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201335_bib20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201335_bib21","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41591-023-02480-8","article-title":"SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial","volume":"29","author":"Papadopoulou","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201335_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005577","article-title":"Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia","volume":"10","author":"Haroun-Izquierdo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201335_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89762","article-title":"A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors","volume":"2","author":"Pavesi","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201335_bib24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241417","article-title":"CD4+ T cell dysfunction in cancer","volume":"222","author":"Venkatesh","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201335_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/2326-6066.CIR-20-0736","article-title":"Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells","volume":"10","author":"Somasundaram","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201335_bib26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201335_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201335_bib28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/jcm9072193","article-title":"Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients","volume":"9","author":"Thongprayoon","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omton.2026.201335_bib29","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/bcp.13952","article-title":"Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients","volume":"85","author":"Lu","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omton.2026.201335_bib30","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe Cytokine-Release Syndrome after T Cell\u2013Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti\u2013IL-6 Therapy Is Safe and Well Tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201335_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.12.296","article-title":"Investigating the Relationship between Cytokine Release Syndrome, Graft-Versus-Host Disease, and One-Year Mortality after Haploidentical Hematopoietic Stem Cell Transplantation","volume":"25","author":"Hsiao","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201335_bib32","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201335_bib33","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/eji.200425933","article-title":"Amelioration of acute graft-versus-host disease by NKG2A engagement on donor T cells","volume":"35","author":"Kawamura","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2026.201335_bib34","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","article-title":"IL-4 drives exhaustion of CD8+ CART cells","volume":"15","author":"Stewart","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201335_bib35","article-title":"An IL-4\/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201335_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201335_bib37","doi-asserted-by":"crossref","first-page":"20428","DOI":"10.1073\/pnas.0811139106","article-title":"IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection","volume":"105","author":"Brooks","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201335_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201335_bib39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201335_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201335_bib41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201335_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1484303","article-title":"Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors","volume":"16","author":"Kadyrzhanova","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926002110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926002110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:14:35Z","timestamp":1791058475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926002110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2950329926002110"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201335","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering \u201coff-the-shelf\u201d TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201335"}}